Lactate Dehydrogenase L-P, (LDH) (NAO), Catalog Number LD3842 - Product Usage: device intended for the quantitative in vitro determination of Lactate Dehydrogenase (LD) activity in serum and plasma. This product is suitable for use on the RX series instruments which includes the RX daytona and RX imola.
Publicado el 23 de septiembre de 2020 · Inicio del retiro: 11 de agosto de 2020
Resumen
FDA registra el retiro Z-2962-2020 de dispositivos médicos de Clase II, publicado el 23 de septiembre de 2020 e iniciado el 11 de agosto de 2020. Empresa responsable: Randox Laboratories Ltd.; Estado: Finalizado; Cantidad reportada: 21; Lote: GTIN: 05055273204124; Lot Numbers: 480483 495947 523902 536342. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
An update to the carryover avoidance technical bulletin to introduce additional steps for reagent carryover avoidance with the Lactate Dehydrogenase assay on RX Instruments. Additional pipette washes can be implemented as described in the technical bulletin. Interference to the Lactate Dehydrogenase (LOH) reagent would be observed as inconsistencies in Quality Control recovery, which may lead to a delay in running patient samples, or erroneous elevated test results.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Randox Laboratories Ltd.
- Distribuidor
- US Nationwide distribution including in the states of WV, and Puerto Rico.
- Lote
- GTIN: 05055273204124; Lot Numbers: 480483 495947 523902 536342
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- Ireland
Retiros relacionados
- FDARX Series CYSC- Cystatin C Reagent -Intended for in vitro diagnostic (IVD) use as Randox Cystatin C assay on31 de julio de 2024
- FDAClinical Chemistry Calibration Serum (Catalog number Cal2351) that is 20x5ml lyophilized human based serum15 de mayo de 2024
- FDAEvidence MultiSTAT with software v 3.7-Analyzer intended for the qualitative determination of parent drug15 de mayo de 2024
- FDAMicroalbumin Calibrator Series (mALB CAL)-IVD used to calibrate the Microalbumin Assay Catalog Number: MA156724 de abril de 2024
- FDAMaquet/Getinge Rotaflow System Console US (115 V / 60 Hz) - Product Usage: Instructions for Use - Centrifugal23 de septiembre de 2020
- FDALactate Dehydrognease P-L, (UV), Catalog Number LD3818 - Product Usage: device intended for the quantitative23 de septiembre de 2020
Preguntas sobre este retiro
¿Lactate Dehydrogenase L-P, (LDH) (NAO), Catalog Number LD3842 - Product Usage: device intended for the quantitative in vitro determination of Lactate Dehydrogenase (LD) activity in serum and plasma. This product is suitable for use on the RX series instruments which includes the RX daytona and RX imola. fue retirado del mercado?
Sí. FDA publicó el retiro Z-2962-2020 el 23 de septiembre de 2020. Peligro reportado: An update to the carryover avoidance technical bulletin to introduce additional steps for reagent carryover avoidance with the Lactate Dehydrogenase assay on RX Instruments. Additional pipette washes can be implemented as described in the technical bulletin. Interference to the Lactate Dehydrogenase (LOH) reagent would be observed as inconsistencies in Quality Control recovery, which may lead to a delay in running patient samples, or erroneous elevated test results.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter